SCIENCE
Why pharma firms are betting billions on psychedelic drugs despite setbacks
NatureTuesday, October 27, 2026 at 12:00 AM
RedScroll Brief
Nature, Published online: 27 October 2026; doi:10. 1038/d41586-026-03390-8 Regulatory pushback stalled the field.
RedScroll Signal
- Impact
- High
- Category
- Science
- Market relevance
- None
- Why it matters
- Scientific signal separates durable discovery from noise — and often foreshadows policy and product. Nature, Published online: 27 October 2026; doi:10. 1038/d41586-026-03390-8 Regulatory pushback stalled the field.
Desk copy
RedScroll Briefing
Extractive editorial brief — not a reprint of the original
What happened
Nature, Published online: 27 October 2026; doi:10. 1038/d41586-026-03390-8 Regulatory pushback stalled the field.
Why it matters
Scientific signal separates durable discovery from noise — and often foreshadows policy and product.
Background
Nature reported on this under science. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.
Timeline
Nature published: Why pharma firms are betting billions on psychedelic drugs despite setbacks
Story is in today’s RedScroll edition. Follow the original source for updates.
More on
Related stories
- AI-hallucinated citations should be treated as research misconduct
NatureSCIENCE
- AI watermarking efforts must encourage independent public scrutiny
NatureSCIENCE
- How to keep tabs on the tools in your lab
NatureSCIENCE
- The Nobel prize in economic science has a serious gender problem
NatureSCIENCE
- Short-term academic visits to China could sustain ties
NatureSCIENCE
- Can science make your dog live longer? Longevity craze comes to pets
NatureSCIENCE
Source
Nature
Original reporting by Nature. RedScroll provides an extractive briefing only.